Histogen to Release Fourth Quarter and Year-End 2020 Financial Results and Provide Business Update

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing first-in-class potential restorative therapies that trigger the body’s natural process to repair and maintain health function biological, today announced that Histogen’s financial results for the fourth quarter and year ended December 31, 2020 will be released after market close on Thursday, March 11, 2021.

About Histogen Inc.

Histogen Inc. is a clinical-stage therapeutics company focused on developing first-in-class, potential restorative therapies that trigger the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform uses cellular conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary and repeatable manufacturing process provides targeted solutions in a wide range of therapeutic indications, including hair growth, dermal rejuvenation, articular cartilage regeneration and spinal disc repair. For more information, please visit www.histogen.com.

CONTACT:

Susan A. Knudson
Executive Vice President and Chief Financial Officer
Histogen Inc.
[email protected]

Comments are closed.